ArticleTransfusion2025
Healthy volunteer stem cell donors followed up 10 years after stimulation with biosimilar filgrastim.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07376460 (Biological and Proteomic Characterisation of Platelet-rich Plasma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biological and Proteomic Characterisation of Platelet-rich Plasma (PRP) Before and After Mobilisation of Haematopoietic Stem Cells in Peripheral Blood From Women With Low Ovarian Response (Low Responders) and in Vitro Evaluation in Human Ovarian Cell Models
Who cites it
2 citing papers in PubMed.
- Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Healthy volunteer stem cell donors followed up 10 years after stimulation with biosimilar filgrastim.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe application of granulocyte colony-stimulating factors (G-CSF) for mobilizing hematopoietic stem and progenitor cells in healthy donors is considered safe. However, only limited safety information is available about long-term adverse events (AEs) in this setting. To determine the long-term effect of health consequences to stem cell donors, 244 G-CSF-mobilized donors were tracked prospectively for 10 years. STUDY DESIGN AND
methodsA total of 244 adult healthy unrelated stem cell donors who received at least one dose of Sandoz biosimilar filgrastim were enrolled in this prospective long-term surveillance study. Safety, mental health, and physical health were followed up over a period of 10 years.
resultsNinety-five percent of the donors experience at least one AE during the stem mobilization period; beyond this period, the onset of the first AE was 3.86 [3.45-4.27] years in females and 4.02 [3.68-4.35] years in males. The risk of reporting an AE was significantly lower in the youngest tertile of donors, when compared to the oldest (p = 0.026). Females were more likely to report AEs than males (0.40 vs. 0.21 AEs/year, rate ratio: 1.87 [CI: 1.32-2.64]; <0.001). No clinically relevant permanent changes occurred up to 10 years from mobilization in physical or mental health. DISCUSSION: No new or excessive AEs were identified during a 10-year follow-up of mobilized stem cell donors and therefore reassure about the overall safety of stem cell mobilization with G-CSF in healthy volunteers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.